Notification of Intent to Use Schedule III, IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment of Opiate Addiction
Extension without change of a currently approved collection
No
Regular
Approved without change
12/14/2022
11/08/2022
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
12/31/2025
36 Months From Approved
01/31/2023
11,683
0
8,163
6,874
0
4,893
0
0
0
The Drug Addiction Treatment Act of 2000 establishes conditions for physicians to obtain waivers to permit them to prescribe certain approved narcotic treatment medications for the maintenance or detoxification treatment of opioid addiction. Under the SUPPORT Act, this data collection will include other practitioners who meet the statutory requirements: nurse practitioners, physician assistants, nurse specialist, nurse-midwives, and registered nurse anesthetists.
SAMHSA will adding three additional forms from OMB No. 0930-0369.
US Code:
21 USC 823
Name of Law: Drug Addiction Treatment Act of 2000
US Code: 21 USC 823 Name of Law: Drug Addiction Treatment Act of 2000
There is an increase in burden due to a 20 percent increase in submission of NOI waiver applications to the program annually. The program has made burden calculation adjustments to account for this increase in waiver applications.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.